Reviewer Relationships With Industry and Other Entities (Relevant): 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guidelines for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease Reviewer Representation Consultant Speaker Ownership/ Partnership/ Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Ralph G. Brindis Official Reviewer ACCF Board of Trustees None None None None None None Timothy D. Henry Official Reviewer AHA CV Therapeutics Sanofi-aventis None None Baxter* CV Therapeutics* None None Judith S. Hochman Official Reviewer ACCF/AHA Task Force on Practice Guidelines Eli Lilly GlaxoSmithKline None None Johnson & Johnson Merck Robert H. Jones Official Reviewer STS None None None None None None Janet B. Long Official Reviewer PCNA None AstraZeneca None None None None Bruce W. Lytle Official Reviewer AATS None None None None None None Douglass A. Morrison Official Reviewer SCAI None None None None None None E. Magnus Ohman Official Reviewer AHA Abiomed Datascope Inovise* Liposcience The Medicines Company Response Biomedical CV Therapeutics* The Medicines Company* Inovise* Bristol-Myers Squibb* Daiichi-Sankyo* Eli Lilly* The Medicines Company* Millennium Pharmaceuticals* Sanofi-aventis* Schering-Plough* None None (Continued) Fihn et al Stable Ischemic Heart Disease: Full Text e467 Appendix 2. 